These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 28215471

  • 1. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.
    Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L.
    Schizophr Res; 2017 Nov; 189():126-133. PubMed ID: 28215471
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [Abstract] [Full Text] [Related]

  • 3. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T, Perry CM.
    Drugs; 2004 May; 64(15):1715-36. PubMed ID: 15257633
    [Abstract] [Full Text] [Related]

  • 5. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ.
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [Abstract] [Full Text] [Related]

  • 8. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [Abstract] [Full Text] [Related]

  • 9. A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.
    Cantillon M, Ings R, Prakash A, Bhat L.
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):573-585. PubMed ID: 29619682
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG.
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [Abstract] [Full Text] [Related]

  • 11. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW.
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
    Casey DE, Sands EE, Heisterberg J, Yang HM.
    Psychopharmacology (Berl); 2008 Oct; 200(3):317-31. PubMed ID: 18597078
    [Abstract] [Full Text] [Related]

  • 14. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I.
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ, APLUS study group.
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [Abstract] [Full Text] [Related]

  • 16. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
    Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H.
    Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H.
    Am J Psychiatry; 2015 Sep 01; 172(9):870-80. PubMed ID: 25882325
    [Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN.
    J Psychiatr Res; 2007 Dec 01; 41(11):895-905. PubMed ID: 17631314
    [Abstract] [Full Text] [Related]

  • 19. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
    Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, Loebel A.
    J Psychiatr Res; 2013 May 01; 47(5):670-7. PubMed ID: 23421963
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
    Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y.
    CNS Drugs; 2009 May 01; 23(7):615-25. PubMed ID: 19552488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.